2022年(nian)版醫保藥(yao)(yao)品(pin)(pin)目(mu)錄(lu)顯示，目(mu)前(qian)中(zhong)國共收載西藥(yao)(yao)和中(zhong)成(cheng)藥(yao)(yao)達(da)2967種(zhong)(zhong)，其中(zhong)西藥(yao)(yao)1586種(zhong)(zhong)，中(zhong)成(cheng)藥(yao)(yao)1381種(zhong)(zhong)。中(zhong)藥(yao)(yao)飲片未作調整，仍為892種(zhong)(zhong)。此(ci)次共111個藥(yao)(yao)品(pin)(pin)新增進入目(mu)錄(lu)，3個藥(yao)(yao)品(pin)(pin)被調出目(mu)錄(lu)。

本次調整新增的111個藥(yao)(yao)品(pin)名單(dan)里，其中(zhong)西(xi)藥(yao)(yao)類有3種(zhong)(zhong)、協議期(qi)內(nei)談(tan)判(pan)藥(yao)(yao)品(pin)部(bu)分 (一)西(xi)藥(yao)(yao)類有83種(zhong)(zhong)、協議期(qi)內(nei)談(tan)判(pan)藥(yao)(yao)品(pin)部(bu)分 (二)中(zhong)成藥(yao)(yao)類有8種(zhong)(zhong)，競價藥(yao)(yao)品(pin)部(bu)分有17種(zhong)(zhong)。

2022醫保(bao)談判目錄新增的74個談判藥品涉及21個臨床組別，其中罕見病(bing)用(yong)藥7種(zhong)，新冠肺(fei)炎(yan)治療用(yong)藥2種(zhong)，其他領域(yu)用(yong)藥12種(zhong)，腫瘤(liu)用(yong)藥18種(zhong)，丙肝(gan)、艾(ai)滋病(bing)等抗(kang)毒感(gan)染用(yong)藥15種(zhong)，高血(xue)壓、糖尿病(bing)、高血(xue)脂(zhi)等慢性病(bing)用(yong)藥20種(zhong)。